Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
saxagliptin 5 MG Oral Tablet [Onglyza]
Known as:
Onglyza (as saxagliptin hydrochloride 5.58 MG) 5 MG Oral Tablet
, onglyza 5 MG Oral Tablet
, saxagliptin hydrochloride 5 mg ORAL TABLET, FILM COATED [ONGLYZA]
National Institutes of Health
Create Alert
Related topics
Related topics
8 relations
Croscarmellose Sodium
Lactose Monohydrate
Magnesium stearate
Onglyza
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Saxagliptin: A Review in Type 2 Diabetes
Sohita Dhillon
Drugs
2015
Corpus ID: 44681511
Saxagliptin (Onglyza®) is a highly potent, reversible, competitive dipeptidyl peptidase-4 inhibitor indicated for the treatment…
Expand
2015
2015
Of the Big Daddy, the Underdog, the Mother Hen, and the Scapegoats: Balancing Pharmaceutical Innovation and Access to Healthcare in the Enforcement of Compulsory Patent Licensing in India, its…
M. Chopra
2015
Corpus ID: 169500374
2014
2014
Saxagliptin: a guide to its use in type 2 diabetes mellitus
K. Lyseng-Williamson
,
L. Yang
2014
Corpus ID: 71371922
Oral saxagliptin (Onglyza®), a potent, selective dipeptidyl pepitase-4 inhibitor, is a useful option to improve glycaemic control…
Expand
2012
2012
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
O. Granström
,
K. Bergenheim
,
P. McEwan
,
K. Sennfält
,
M. Henriksson
Primary care diabetes
2012
Corpus ID: 37541961
AIM The objective of this study was to investigate the cost-effectiveness of saxagliptin (Onglyza(®)), a DPP-4 inhibitor, plus…
Expand
Review
2012
Review
2012
Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
L. Yang
Drugs
2012
Corpus ID: 195687875
Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the treatment of type 2 diabetes mellitus. In…
Expand
2012
2012
Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method…
X. Xu
,
Roger Demers
,
+8 authors
M. Arnold
Journal of chromatography. B, Analytical…
2012
Corpus ID: 28459287
A liquid chromatography and tandem mass spectrometry (LC-MS/MS) method was developed and validated to simultaneously determine…
Expand
2012
2012
Effect of saxagliptin on the pharmacokinetics of the active components of Ortho‐Cyclen®, a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women
V. Upreti
,
C. Hsiang
,
L. Li
,
X. Xu
,
F. Lacreta
,
D. Boulton
Diabetes, obesity & metabolism
2012
Corpus ID: 8042901
Saxagliptin (Onglyza™) is a dipeptidyl peptidase‐4 (DPP4) inhibitor for treating type 2 diabetes mellitus. This open‐label…
Expand
2012
2012
PDB53 Cost-Effectiveness of Saxagliptin (Onglyza®) in Type 2 Diabetes in South Africa
A. Juárez-García
,
D. Casalvolone
,
L. Qatami
,
K. Bergenheim
,
B.M.K. Donato
2012
Corpus ID: 71458195
2010
2010
Saxagliptin for type 2 diabetes
A. Chacra
Diabetes, metabolic syndrome and obesity…
2010
Corpus ID: 31343898
Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving…
Expand
2010
2010
La saxagliptine (Onglyza®) - un nouvel inhibiteur de la DPP-4 pour le traitement oral du diabète de type 2
M. Hermans
2010
Corpus ID: 78587651
• L'enzyme DPP-4 degrade physiologiquement les incretines GLP-1 et GIP. • La saxagliptine (Onglyza ® ) est un inhibiteur oral de…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE